NASDAQ:AKBA

Akebia Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy AKBA

*Your capital is at risk

$1.38

-0.0200 (-1.43%)

At Close: Jul 13, 2026

Currently predicting for Tue, 14 Jul 2026

AKBA Live board

Community Bull/Bear

Target Next close

Join the AKBA prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

AKBA Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For AKBA

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

AKBA Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT AKEBIA THERAPEUTICS

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	10.58%	Jun 29
NMRK $15.02	0.466%	Jun 24
X XMAX $8.34	2.40%	Jun 24
NESR $25.07	12.49%	Jun 23
CAG $13.43	6.70%	Jun 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by